Physician profile
Joseph Cottone
NPI 1639177447
$5,865.60
in general payments reported to CMS, 2019-2025
35 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $66.81 · 2021: $80.37 · 2022: $1,749 · 2023: $338 · 2024: $1,301 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,519 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,518.94 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,729.16 | 2021-2025 | Barrigel, Urolift |
| Janssen Biotech, INC. | $428.12 | 2019-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $356.76 | 2019-2025 | Xtandi |
| Boston Scientific Corporation | $346.02 | 2019-2025 | Axonics |
| Endo USA, INC. | $271.72 | 2024-2025 | Aveed, Xiaflex |
| Calyxo, INC. | $269.14 | 2025 | Cvac Aspiration System |
| Dendreon Pharmaceuticals LLC | $267.20 | 2024-2025 | Provenge |
| Siemens Medical Solutions USA, INC. | $261.65 | 2024-2025 | Magnetom Sola, Magnetom Vida |
| Sumitomo Pharma America, INC. | $200.59 | 2024-2025 | Orgovyx, Gemtesa |
| Urovant Sciences INC | $185.05 | 2022 | |
| Olympus America INC. | $173.61 | 2021-2025 | Itind System, Soltive, Gyrus Acmi |
| Pfizer INC. | $172.56 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.33 | 2024-2025 | |
| Urogen Pharma, INC. | $137.87 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $112.05 | 2019-2024 | Bard Urinary Drainage Bag |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $103.13 | 2024 | Aquabeam System |
| Accord Healthcare, INC. | $91.86 | 2022-2023 | |
| Coloplast Corp | $85.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $64.46 | 2024-2025 | Lynparza, Bridion |
| Myriad Genetic Laboratories, INC. | $61.10 | 2024-2025 | Prolaris |
| Ferring Pharmaceuticals INC. | $60.90 | 2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $58.34 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $51.34 | 2019-2024 | Erleada, Akeega |
| Karl Storz Endoscopy-America | $39.10 | 2022 | |
| Antares Pharma, INC. | $32.12 | 2024 | Xyosted |
| Steris Corporation | $23.57 | 2024 | |
| 180 Medical, INC. | $20.67 | 2024 | |
| Profound Medical Corp. | $19.87 | 2025 | Tulsa-Pro |
| Progenics Pharmaceuticals, INC. | $18.24 | 2024 | |
| Telix Pharmaceuticals | $17.02 | 2025 | Illuccix |
| Vertex Pharmaceuticals Incorporated | $16.15 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.81 | 2025 | Azmiro |
| Abbvie INC. | $12.92 | 2019 | |
| Eagle Pharmaceuticals, INC. | $12.74 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cottone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.